Role of chronic inflammation as a predictor of upstaging/upgrading in prostate cancer: Finding a new group eligible for active surveillance | Nowroozi | Urology Journal

Role of chronic inflammation as a predictor of upstaging/upgrading in prostate cancer: Finding a new group eligible for active surveillance | Nowroozi | Urology Journal: Role of chronic inflammation as a predictor of upstaging/upgrading in prostate cancer: Finding a new group eligible for active surveillance

Comments

Post a Comment

Popular posts from this blog

Dr. Christopher Kane of UCSD Health Appointed Chairman of the American Board of Urology

Image
  Dr. Christopher Kane of UCSD Health Appointed Chairman of the American Board of Urology SAN DIEGO, May 21, 2025 - Dr. Christopher Kane, a distinguished urologist and Professor of Urology at UC San Diego Health, has been appointed Chairman of the American Board of Urology (ABU), the organization announced today. Dr. Kane, who has served as CEO of UC San Diego Health Physician Group and Dean of Clinical Affairs at the UC San Diego School of Medicine, brings decades of experience in urologic oncology and leadership to this prestigious national position. Extensive Academic and Research Background Dr. Kane earned his medical degree from Uniformed Services University in Bethesda, Maryland, followed by a residency in urology at the Naval Medical Center San Diego and a fellowship in urologic oncology at the National Cancer Institute. He joined the UCSD faculty in 2007 after serving as a Navy physician for 12 years. As the C. Lowell and JoEllen Parsons Endowed Chair in Urology, Dr. ...
Read more

PSMA-Targeted Therapies for Prostate Cancer: Move Treatment Earlier in Disease Course

Image
  Interactive Graphic PSMA-Targeted Therapies for Prostate Cancer: Move Treatment Earlier in Disease Course Landmark FDA approval expands access to radioligand therapy while new research explores next-generation treatments By [Your Name] for the IPCSG Newsletter The landscape of prostate cancer treatment has undergone a seismic shift in recent months, with groundbreaking advances in prostate-specific membrane antigen (PSMA)-targeted therapies offering new hope to patients across different stages of the disease. Most significantly, the FDA's March 2025 expansion of Pluvicto (lutetium-177-PSMA-617) approval now allows treatment before chemotherapy, potentially tripling the number of eligible patients. Major FDA Approval Expands Treatment Access On March 28, 2025, the FDA approved a crucial expansion of Pluvicto's indication, allowing its use in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen recepto...
Read more

ASCO 2025: Non-Androgen-Receptor–Driven Prostate Cancer: Updates in Biology, Classification, and Management

Image
New Hope for Aggressive Prostate Cancer: Advances in Understanding and Treating Neuroendocrine Prostate Cancer Revolutionary diagnostic tools and promising new therapies offer renewed hope for patients with treatment-resistant disease What Patients Need to Know For most men with prostate cancer, treatments targeting the androgen receptor (AR) pathway—including hormone therapy and newer drugs like enzalutamide and abiraterone—are highly effective. However, as these treatments have become more successful, doctors have observed an important but concerning phenomenon: some cancers develop resistance by essentially changing their identity. This transformation, called neuroendocrine prostate cancer (NEPC), represents one of the most aggressive forms of the disease. At the recent 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Himisha Beltran from Dana-Farber Cancer Institute presented groundbreaking research that offers new hope for patients facing this challenging ...
Read more